{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T03:00:56Z","timestamp":1784948456441,"version":"3.55.0"},"reference-count":64,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,12,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare myeloid malignancy with no defined standard of care. BPDCN presents most commonly with skin lesions with or without extramedullary organ involvement before leukemic dissemination. As a result of its clinical ambiguity, differentiating BPDCN from benign skin lesions or those of acute myeloid leukemia with leukemia cutis is challenging. BPDCN is most easily defined by the phenotype CD4+CD56+CD123+lineage\u2013MPO\u2013, although many patients will present with variable expression of CD4, CD56, or alternate plasmacytoid markers, which compounds the difficulty in differentiating BPDCN from other myeloid or lymphoid malignancies. Chromosomal aberrations are frequent, and the mutational landscape of BPDCN is being rapidly characterized although no obvious molecular target for chemoimmunotherapy has been identified. Chemotherapy regimens developed for acute myeloid leukemia, acute lymphoid leukemia, and myelodysplastic syndrome have all been used to treat BPDCN. Relapse is frequent, and overall survival is quite poor. Allogeneic transplantation offers a chance at prolonged remission and possible cure for those who are eligible; unfortunately, relapse remains high ranging from 30% to 40%. Novel therapies such as SL-401, a diphtheria toxin conjugated to interleukin-3 (IL-3) is commonly overexpressed in BPDCN and other aggressive myeloid malignancies and has shown considerable promise in ongoing clinical trials. Future work with SL-401 will define its place in treating relapsed or refractory disease as well as its role as a first-line therapy or bridge to transplantation.<\/jats:p>","DOI":"10.1182\/asheducation-2016.1.16","type":"journal-article","created":{"date-parts":[[2016,12,2]],"date-time":"2016-12-02T11:05:27Z","timestamp":1480676727000},"page":"16-23","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":67,"title":["Treatment of blastic plasmacytoid dendritic cell neoplasm"],"prefix":"10.1182","volume":"2016","author":[{"given":"Jill M.","family":"Sullivan","sequence":"first","affiliation":[{"name":"Duke Cancer Institute, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Rizzieri","sequence":"additional","affiliation":[{"name":"Duke Cancer Institute, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111704403663800_B1","first-page":"145","article-title":"Blastic plasmacytoid dendritic cells neoplasm","volume-title":"WHO classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Facchetti","year":"2008"},{"issue":"7","key":"2019111704403663800_B2","doi-asserted-by":"crossref","first-page":"3778","DOI":"10.1182\/blood-2007-10-117531","article-title":"Novel markers of normal and neoplastic human plasmacytoid dendritic cells","volume":"111","author":"Marafioti","year":"2008","journal-title":"Blood"},{"issue":"6","key":"2019111704403663800_B3","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1097\/PAP.0b013e3181bb6bc2","article-title":"Plasmacytoid dendritic cells: physiologic roles and pathologic states","volume":"16","author":"Jegalian","year":"2009","journal-title":"Adv Anat Pathol"},{"issue":"3","key":"2019111704403663800_B4","doi-asserted-by":"crossref","first-page":"210","DOI":"10.3109\/08916930903510898","article-title":"Tumoral aspects of plasmacytoid dendritic cells: what do we know in 2009?","volume":"43","author":"Petrella","year":"2010","journal-title":"Autoimmunity"},{"issue":"1","key":"2019111704403663800_B5","first-page":"58","article-title":"Incidence and characteristics of CD4(+)\/HLA DRhi dendritic cell malignancies","volume":"89","author":"Bueno","year":"2004","journal-title":"Haematologica"},{"issue":"2","key":"2019111704403663800_B6","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000334703","article-title":"Blastic plasmacytoid dendritic cell neoplasm without cutaneous lesion at presentation: case report and literature review","volume":"127","author":"Wang","year":"2012","journal-title":"Acta Haematol"},{"issue":"5","key":"2019111704403663800_B7","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1309\/FY6PK436NBK0RYD4","article-title":"CD4+\/CD56+ hematodermic tumor: the features of an evolving entity and its relationship to dendritic cells","volume":"127","author":"Herling","year":"2007","journal-title":"Am J Clin Pathol"},{"issue":"8","key":"2019111704403663800_B8","first-page":"941","article-title":"CD4+ CD56+ lineage negative malignancies: a new entity developed from malignant early plasmacytoid dendritic cells","volume":"88","author":"Jacob","year":"2003","journal-title":"Haematologica"},{"issue":"7","key":"2019111704403663800_B9","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1093\/annonc\/mdh268","article-title":"CD56+ hematological neoplasms presenting in the skin: a retrospective analysis of 23 new cases and 130 cases from the literature","volume":"15","author":"Bekkenk","year":"2004","journal-title":"Ann Oncol"},{"issue":"17","key":"2019111704403663800_B10","doi-asserted-by":"crossref","first-page":"4591","DOI":"10.1182\/blood-2011-03-337501","article-title":"Twenty-one cases of blastic plasmacytoid dendritic cell neoplasm: focus on biallelic locus 9p21.3 deletion","volume":"118","author":"Lucioni","year":"2011","journal-title":"Blood"},{"issue":"9","key":"2019111704403663800_B11","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1002\/cncr.10489","article-title":"CD56(+) TdT(+) blastic natural killer cell tumor of the skin: a primitive systemic malignancy related to myelomonocytic leukemia","volume":"94","author":"Khoury","year":"2002","journal-title":"Cancer"},{"issue":"5","key":"2019111704403663800_B12","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1182\/blood.V99.5.1556","article-title":"Clinical and biologic features of CD4(+)CD56(+) malignancies","volume":"99","author":"Feuillard","year":"2002","journal-title":"Blood"},{"issue":"12","key":"2019111704403663800_B13","doi-asserted-by":"crossref","first-page":"5007","DOI":"10.1182\/blood-2002-10-3297","article-title":"TCL1 expression in plasmacytoid dendritic cells (DC2s) and the related CD4+ CD56+ blastic tumors of skin","volume":"101","author":"Herling","year":"2003","journal-title":"Blood"},{"issue":"4","key":"2019111704403663800_B14","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1046\/j.1365-2133.2003.05639.x","article-title":"Blastic natural killer-cell lymphoma of the skin associated with myelodysplastic syndrome or myelogenous leukaemia: a coincidence or more?","volume":"149","author":"Kazakov","year":"2003","journal-title":"Br J Dermatol"},{"issue":"4","key":"2019111704403663800_B15","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/ajh.2830470406","article-title":"High expression of CD56 (N-CAM) in a patient with cutaneous CD4-positive lymphoma","volume":"47","author":"Adachi","year":"1994","journal-title":"Am J Hematol"},{"issue":"4","key":"2019111704403663800_B16","doi-asserted-by":"crossref","first-page":"564","DOI":"10.5858\/arpa.2013-0101-RS","article-title":"Blastic plasmacytoid dendritic cell neoplasm: a clinicopathologic review","volume":"138","author":"Shi","year":"2014","journal-title":"Arch Pathol Lab Med"},{"issue":"3","key":"2019111704403663800_B17","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1309\/AJCP9IS9KFSVWKGH","article-title":"Immunophenotypic analysis of myeloperoxidase-negative leukemia cutis and blastic plasmacytoid dendritic cell neoplasm","volume":"137","author":"Cronin","year":"2012","journal-title":"Am J Clin Pathol"},{"issue":"1","key":"2019111704403663800_B18","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/PAS.0b013e3181c5e26b","article-title":"Cutaneous manifestations of blastic plasmacytoid dendritic cell neoplasm-morphologic and phenotypic variability in a series of 33 patients","volume":"34","author":"Cota","year":"2010","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"2019111704403663800_B19","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2340\/00015555-1458","article-title":"Cutaneous myeloid sarcoma: natural history and biology of an uncommon manifestation of acute myeloid leukemia","volume":"93","author":"Hurley","year":"2013","journal-title":"Acta Derm Venereol"},{"issue":"2","key":"2019111704403663800_B20","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3324\/haematol.13855","article-title":"Cytoplasmic nucleophosmin is not detected in blastic plasmacytoid dendritic cell neoplasm","volume":"94","author":"Facchetti","year":"2009","journal-title":"Haematologica"},{"issue":"11","key":"2019111704403663800_B21","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/j.1600-0560.2011.01777.x","article-title":"Cutaneous accumulation of plasmacytoid dendritic cells associated with acute myeloid leukemia: a rare condition distinct from blastic plasmacytoid dendritic cell neoplasm","volume":"38","author":"Dargent","year":"2011","journal-title":"J Cutan Pathol"},{"issue":"5","key":"2019111704403663800_B22","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1097\/00000478-200405000-00004","article-title":"Nodal and extranodal tumor-forming accumulation of plasmacytoid monocytes\/interferon-producing cells associated with myeloid disorders","volume":"28","author":"Vermi","year":"2004","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"2019111704403663800_B23","first-page":"ELT10","article-title":"The CD4+ CD56+ CD116- CD123+ CD45RA+ CD45RO- profile is specific of DC2 malignancies","volume":"88","author":"Trimoreau","year":"2003","journal-title":"Haematologica"},{"key":"2019111704403663800_B24","first-page":"145","volume-title":"Blastic plasmacytoid denritic cell neoplasm","author":"Facchetti","year":"2008"},{"issue":"10","key":"2019111704403663800_B25","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/j.1600-0560.2007.00915.x","article-title":"CD4-negative variant of CD4+\/CD56+ hematodermic neoplasm: description of three cases","volume":"35","author":"Ascani","year":"2008","journal-title":"J Cutan Pathol"},{"issue":"8","key":"2019111704403663800_B26","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1038\/modpathol.2013.238","article-title":"Optimized immunohistochemical panel to differentiate myeloid sarcoma from blastic plasmacytoid dendritic cell neoplasm","volume":"27","author":"Sangle","year":"2014","journal-title":"Mod Pathol"},{"issue":"3","key":"2019111704403663800_B27","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/ajh.24258","article-title":"Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: 10-Color flow cytometry diagnosis and HyperCVAD therapy","volume":"91","author":"Deotare","year":"2016","journal-title":"Am J Hematol"},{"issue":"5","key":"2019111704403663800_B28","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1111\/j.1365-2141.2009.07679.x","article-title":"Extended diagnostic criteria for plasmacytoid dendritic cell leukaemia","volume":"145","author":"Garnache-Ottou","year":"2009","journal-title":"Br J Haematol"},{"issue":"11","key":"2019111704403663800_B29","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.1182\/blood.V99.11.4154","article-title":"CD4(+), CD56(+) DC2 acute leukemia is characterized by recurrent clonal chromosomal changes affecting 6 major targets: a study of 21 cases by the Groupe Fran\u00e7ais de Cytog\u00e9n\u00e9tique H\u00e9matologique","volume":"99","author":"Leroux","year":"2002","journal-title":"Blood"},{"key":"2019111704403663800_B30","first-page":"9","article-title":"Simultaneous deletion of 3\u2032ETV6 and 5\u2032EWSR1 genes in blastic plasmacytoid dendritic cell neoplasm: case report and literature review","author":"Tang","year":"2016","journal-title":"Mol Cytogenet"},{"issue":"2","key":"2019111704403663800_B31","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3324\/haematol.2012.072645","article-title":"Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study","volume":"98","author":"Pagano","year":"2013","journal-title":"Haematologica"},{"issue":"4","key":"2019111704403663800_B32","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1038\/jid.2009.369","article-title":"Alterations of the cell-cycle inhibitors p27(KIP1) and p16(INK4a) are frequent in blastic plasmacytoid dendritic cell neoplasms","volume":"130","author":"Wiesner","year":"2010","journal-title":"J Invest Dermatol"},{"issue":"4","key":"2019111704403663800_B33","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/leu.2008.359","article-title":"Recurrent genomic aberrations combined with deletions of various tumour suppressor genes may deregulate the G1\/S transition in CD4+CD56+ haematodermic neoplasms and contribute to the aggressiveness of the disease","volume":"23","author":"Jardin","year":"2009","journal-title":"Leukemia"},{"issue":"15","key":"2019111704403663800_B34","doi-asserted-by":"crossref","first-page":"6404","DOI":"10.18632\/oncotarget.2223","article-title":"Targeted ultra-deep sequencing reveals recurrent and mutually exclusive mutations of cancer genes in blastic plasmacytoid dendritic cell neoplasm","volume":"5","author":"Stenzinger","year":"2014","journal-title":"Oncotarget"},{"issue":"4","key":"2019111704403663800_B35","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/leu.2013.283","article-title":"Exome sequencing reveals novel and recurrent mutations with clinical impact in blastic plasmacytoid dendritic cell neoplasm","volume":"28","author":"Menezes","year":"2014","journal-title":"Leukemia"},{"issue":"8","key":"2019111704403663800_B36","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/j.bbmt.2016.03.022","article-title":"Blastic Plasmacytoid Dendritic Cell Neoplasm: From Origin of the Cell to Targeted Therapies","volume":"22","author":"Laribi","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"2019111704403663800_B37","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.bbmt.2013.01.027","article-title":"Diagnostic and therapeutic advances in blastic plasmacytoid dendritic cell neoplasm: a focus on hematopoietic cell transplantation","volume":"19","author":"Kharfan-Dabaja","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"2019111704403663800_B38","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.bbmt.2010.12.706","article-title":"Blastic plasmacytoid dendritic cell neoplasia (BPDC) in elderly patients: results of a treatment algorithm employing allogeneic stem cell transplantation with moderately reduced conditioning intensity","volume":"17","author":"Dietrich","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"2019111704403663800_B39","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/sj.bmt.1704215","article-title":"What is CD4+CD56+ malignancy and how should it be treated?","volume":"32","author":"Reimer","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"2019111704403663800_B40","first-page":"30","article-title":"Analysis of outcomes of patients (pts) with blastic plasmacytoid dendritic cell neoplasm (BPDCN) [abstract]","author":"Pemmaraju","year":"2012","journal-title":"J Clin Oncol"},{"issue":"22","key":"2019111704403663800_B41","doi-asserted-by":"crossref","first-page":"19204","DOI":"10.18632\/oncotarget.4146","article-title":"Classification and clinical behavior of blastic plasmacytoid dendritic cell neoplasms according to their maturation-associated immunophenotypic profile","volume":"6","author":"Mart\u00edn-Mart\u00edn","year":"2015","journal-title":"Oncotarget"},{"issue":"23","key":"2019111704403663800_B42","doi-asserted-by":"crossref","first-page":"3559","DOI":"10.1182\/blood-2015-01-621268","article-title":"Long-term survival following autologous and allogeneic stem cell transplantation for blastic plasmacytoid dendritic cell neoplasm","volume":"125","author":"Aoki","year":"2015","journal-title":"Blood"},{"issue":"2","key":"2019111704403663800_B43","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s12185-010-0655-0","article-title":"Blastic plasmacytoid dendritic cell neoplasm should be treated with acute leukemia type induction chemotherapy and allogeneic stem cell transplantation in first remission","volume":"92","author":"Male","year":"2010","journal-title":"Int J Hematol"},{"issue":"8","key":"2019111704403663800_B44","doi-asserted-by":"crossref","first-page":"e102","DOI":"10.1200\/JCO.2011.35.8143","article-title":"Allogeneic stem-cell transplantation for blastic plasmacytoid dendritic cell neoplasm","volume":"30","author":"Ham","year":"2012","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111704403663800_B45","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1182\/blood-2012-08-448613","article-title":"Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European Group for Blood and Marrow Transplantation","volume":"121","author":"Roos-Weil","year":"2013","journal-title":"Blood"},{"issue":"9","key":"2019111704403663800_B46","doi-asserted-by":"crossref","first-page":"10174","DOI":"10.18632\/oncotarget.7101","article-title":"Blastic plasmacytoid dendritic cell neoplasm frequently shows occult central nervous system involvement at diagnosis and benefits from intrathecal therapy","volume":"7","author":"Mart\u00edn-Mart\u00edn","year":"2016","journal-title":"Oncotarget"},{"issue":"5","key":"2019111704403663800_B47","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1038\/bmt.2009.270","article-title":"GVL effect in plasmacytoid DC leukemia\/lymphoma","volume":"45","author":"Kaloyannidis","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"2019111704403663800_B48","author":"Steinberg","year":"2011"},{"issue":"6","key":"2019111704403663800_B49","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/bmt.2012.242","article-title":"Unrelated SCT induces long-term remission in patients with blastic plasmacytoid dendritic cell neoplasm","volume":"48","author":"Unteregger","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"2019111704403663800_B50","first-page":"2603","article-title":"Sustained complete remission of a limited-stage blastic plasmacytoid dendritic cell neoplasm followed by a simultaneous combination of low-dose DeVIC therapy and radiation therapy: a case report and review of the literature","volume":"6","author":"Sugimoto","year":"2013","journal-title":"Int J Clin Exp Pathol"},{"issue":"5","key":"2019111704403663800_B51","first-page":"8204","article-title":"Radiation therapy for cutaneous blastic plasmacytoid dendritic cell neoplasm: a case report and review of the literature","volume":"8","author":"Ishibashi","year":"2015","journal-title":"Int J Clin Exp Med"},{"issue":"3","key":"2019111704403663800_B52","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.jaad.2007.12.012","article-title":"CD4+ CD56+ hematodermic\/plasmacytoid dendritic cell tumor with response to pralatrexate","volume":"58","author":"Leitenberger","year":"2008","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"2019111704403663800_B53","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/ejh.12294","article-title":"Blastic plasmacytoid dendritic cell neoplasm: the first report of two cases treated by 5-azacytidine","volume":"93","author":"Laribi","year":"2014","journal-title":"Eur J Haematol"},{"issue":"11","key":"2019111704403663800_B54","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.3109\/10428194.2016.1160084","article-title":"Azacitidine in the treatment of blastic plasmacytoid dendritic cell neoplasm: a report of 3 cases","volume":"57","author":"Khwaja","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"2019111704403663800_B55","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1038\/sj.leu.2401903","article-title":"The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells","volume":"14","author":"Jordan","year":"2000","journal-title":"Leukemia"},{"issue":"12","key":"2019111704403663800_B56","first-page":"1261","article-title":"Interleukin-3 receptor alpha chain (CD123) is widely expressed in hematologic malignancies","volume":"86","author":"Mu\u00f1oz","year":"2001","journal-title":"Haematologica"},{"issue":"3","key":"2019111704403663800_B57","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1080\/10428190400013712","article-title":"The role of interleukin-3 in classical Hodgkin\u2019s disease","volume":"46","author":"Aldinucci","year":"2005","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"2019111704403663800_B58","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/bjh.12978","article-title":"SL-401 and SL-501, targeted therapeutics directed at the interleukin-3 receptor, inhibit the growth of leukaemic cells and stem cells in advanced phase chronic myeloid leukaemia","volume":"166","author":"Frolova","year":"2014","journal-title":"Br J Haematol"},{"issue":"8","key":"2019111704403663800_B59","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1182\/blood-2002-03-0852","article-title":"Elevated expression of IL-3Ralpha in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis","volume":"100","author":"Testa","year":"2002","journal-title":"Blood"},{"issue":"10","key":"2019111704403663800_B60","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.1182\/blood.V97.10.3210","article-title":"Identification of a leukemic counterpart of the plasmacytoid dendritic cells","volume":"97","author":"Chaperot","year":"2001","journal-title":"Blood"},{"issue":"2","key":"2019111704403663800_B61","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3324\/haematol.2014.111740","article-title":"In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent","volume":"100","author":"Angelot-Delettre","year":"2015","journal-title":"Haematologica"},{"issue":"3","key":"2019111704403663800_B62","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1080\/10428190701799035","article-title":"Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia","volume":"49","author":"Frankel","year":"2008","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"2019111704403663800_B63","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1182\/blood-2014-04-566737","article-title":"Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients","volume":"124","author":"Frankel","year":"2014","journal-title":"Blood"},{"issue":"6","key":"2019111704403663800_B64","first-page":"1730","article-title":"A diphtheria toxin-interleukin 3 fusion protein is cytotoxic to primitive acute myeloid leukemia progenitors but spares normal progenitors","volume":"62","author":"Feuring-Buske","year":"2002","journal-title":"Cancer Res"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2016\/1\/16\/1250670\/hem088332.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2016\/1\/16\/1250670\/hem088332.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T04:41:20Z","timestamp":1573965680000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2016\/1\/16\/21044\/Treatment-of-blastic-plasmacytoid-dendritic-cell"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,2]]},"references-count":64,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12,2]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2016.1.16","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,2]]}}}